arrow
G

Giovanna Cutrona

irccs aou san martino ist
H指数:36
被引数:4,607

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunogenetic Architecture of Chronic Lymphocytic Leukemia at Early Stage: Insights from the O-CLL1 Cohort

慢性淋巴细胞白血病的免疫遗传学架构:来自O-CLL1队列的见解

2026-04-070
OAAI
To Treat or Not to Treat: Navigating Early-Stage CLL in the Era of Targeted Therapy

治疗还是不治疗:靶向治疗时代早期慢性淋巴细胞白血病的治疗选择

2026-01-010
OAAI
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study

MicroRNA分析作为慢性淋巴细胞白血病首次治疗时间的预测指标: 来自O-CLL1前瞻性研究的见解

2024-08-230
OAAI
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy
2023-08-315
OAAI
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia
2023-04-170
PRE
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells

MiR-146b-5p调节慢性淋巴细胞白血病细胞中IL-23受体复合物的表达

2022-10-138
OAAI
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study

慢性淋巴细胞白血病中亚克隆TP53突变谱: 下一代测序回顾性研究

2022-08-183
OAAI
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells

LINC00152在正常和慢性淋巴细胞白血病b细胞中的表达

2021-10-284
OAAI
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia

淋巴细胞倍增时间是预测早期慢性淋巴细胞白血病首次治疗时间的关键预后因素

2021-08-029
OAAI
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

靶向治疗时代的TP53破坏是危险因素: 525例慢性淋巴细胞白血病病例的多中心回顾性研究

2021-05-2511
OA
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials

依鲁替尼作为慢性淋巴细胞白血病患者一线治疗的有效性及与利妥昔单抗-苯达莫司汀的间接比较: 临床试验以外的486例研究结果

2021-05-033
OAAI
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients

人类多能干细胞鉴定慢性淋巴细胞白血病患者12三体的分子靶标

2021-03-014
OA
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

4因素评分的评估: 对接受依鲁替尼的586例CLL患者的回顾性分析。校园CLL研究

2021-02-2414
OAAI
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?

PRIMA-1和PRIMA-1Met (APR246) 在血液系统恶性肿瘤中的抗肿瘤作用: 仍然是突变的P53-Dependent事件?

CELLS
IF5.2
2021-01-0729
OAAI
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients

慢性淋巴细胞白血病的首次治疗时间和P53功能障碍: 早期患者的O-CLL1研究结果

2020-10-2812
OAAI
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab

接受idelalisib-利妥昔单抗治疗的复发/难治性CLL患者的生存风险评分 (SRS) 的验证

2020-09-1612
OAAI
Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNFα, IL-6 and IL-11 cytokines

慢性淋巴细胞白血病细胞损害成骨细胞生成并促进破骨细胞生成: tnf α,IL-6和IL-11细胞因子的作用

2020-08-2713
OAAI